Table 1 Patient’s demographics.

From: Predictive significance of circulating tumor DNA against patients with T790M-positive EGFR-mutant NSCLC receiving osimertinib

Different variables

N = 40 (%)

Age (year)

Median (range)

69 (33–85)

Gender

Male/Female

12/28 (30.0/70.0)

Clinical stage

III/IV/Ope rec.

4/30/6 (10.0/75.0/15.0)

Smoking history

Yes/No

9/31 (22.4/77.6)

ECOG PS

0–1/2

35/5 (87.5/12.5)

Histology

AC/other

40/0 (100/0)

EGFR mutation status

Exon 19/L858R/L861Q

24/15/1 (60.0/37.5/2.5)

Numbers of prior treatment

1/2 or more lines

29/11 (72.5/27.5)

Prior EGFR-TKIs regimens

Gefitinib/Erlotinib/Afatinib

11/12/17 (27.5/30.0/42.5)

Brain metastases

Yes/No

17/23 (42.5/57.5)

PD-L1 expression

≥ 50%/< 50%/unknown

1/17/22 (2.5/42.5/55.0)

  1. ECOG, eastern cooperative oncology group; PS, performance status; PD-L1, programmed death ligand-1; AC, adenocarcinoma; EGFR, epidermal growth factor receptor; TKIs, tyrosine kinase inhibitors; Ope rec, recurrence after operation.
Back to article page